Clene Nanomedicine is trying to set a new “gold standard” in neurodegenerative diseases through the development of a new class of drugs called bioenergetic nanotherapeutics that harnesses the properties of gold nanocrystals.

“We are fortunate to collaborate with CalciMedica, a pharmaceutical company who specializes in developing drugs suppressing calcium overload in the immune cells,” Tvrdik said. “We share the vison that our research might help to identify an effective drug that will improve the recovery of stroke survivors.”

Vaxart, a San Francisco-based biotechnology company, is testing a tablet-form Covid-19 vaccine to tackle storage temperature problems, which affect even rich countries like the US, said founder Sean Tucker. “If it turns out that we will need to vaccinate people every year, it’s going to be a real challenge,” he added. “A tablet vaccine like ours … we dream that it’s going to be sent by mail, or even drone or some other delivery service, because it is room temperature stable, so you don’t have to deal with the problems with the cold-chain [infrastructure].”

Clene Nanomedicine is a clinical-stage biopharmaceutical company focused on treating neurodegenerative diseases. Its chief asset is CNM-Au8, a bioenergetic nanocatalyst under development as an add-on treatment for neurodegenerative diseases like Parkinson’s disease, multiple sclerosis, and Amyotrophic Lateral Sclerosis. CNM-Au8 is part of a new class of drugs called bioenergetic nanotherapeutics that harnesses the properties of gold nanocrystals.

Cue Biopharma has managed to persevere through the COVID pandemic by employing a variety of strategies. President and Chief Scientific Officer, Anish Suri, and Ken Pienta, acting Chief Medical Officer discuss their experiences.

Chiasma was trading 4% higher in the opening minutes on Wednesday.

Cambridge Science Park-based Cerevance has confirmed positive results from a trial of a potential treatment for cognitive impairment associated with schizophrenia.